The California State Legislature passed the California Cancer Care Equity Act (SB 987), a bill that would expand access to specialized cancer care for Medi-Cal patients who receive a complex cancer diagnosis.
Kansas Governor Laura Kelly has proclaimed September “Comprehensive Cancer Centers Awareness Month” in recognition of The University of Kansas Cancer Center becoming designated as a Comprehensive Cancer Center by NCI.
The James P. Allison Institute at MD Anderson Cancer Center established an 11-person scientific advisory board to provide strategic guidance and evaluation of its research portfolio and programs.
NCI will award $23 million to four academic institutions to establish centers of excellence that will conduct research on the role of telehealth in delivering cancer-related health care, a practice that became more prevalent during the COVID-19 pandemic.
Paula M. Fracasso was named deputy director of Massey Cancer Center and senior vice president of the cancer service line at VCU Health.
Mayo Clinic named four enterprise deputy directors to the newly formed enterprise executive leadership team to lead the transformation and integration of the institutional cancer practice at all Mayo Clinic sites.
Sophia George was named the inaugural associate director of diversity, equity, and inclusion, and Ashish Shah was named director of clinical trials and translational research and principal investigator in the Section of Virology and Immunotherapy at Sylvester Comprehensive Cancer Center’s Brain Tumor Initiative at the University of Miami Miller School of Medicine.
The Oversight Committee of the Cancer Prevention and Research Institute of Texas, approved a large slate of awards totaling over $89 million for cancer research, prevention and product development. The list of grants is included below.
A study led by researchers at NCI demonstrated that older adults who participate weekly in many different types of leisure time activities, such as walking for exercise, jogging, swimming laps, or playing tennis, may have a lower risk of death from any cause, as well as death from cardiovascular disease and cancer.
Young B-ALL patients who received doses of tisagenlecleucel, a chimeric antigen receptor T cell (CAR T) therapy, at the higher end of the FDA-approved dosing range had significantly better survival rates at one year compared with those who received lower doses within this range.
